Merck’s attempt to use Lynparza to boost Keytruda in metastatic non-small cell lung cancer has come up short with a second pivotal trial failure. Replacing the chemotherapy pemetrexed with Lynparza ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Merck (NYSE:MRK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its blockbuster anti-PD-1 therapy Keytruda in combination with ...

After crowning Keytruda as the first immunotherapy for advanced cervical cancer back in 2021, the FDA has awarded the drug another industry-first designation in an earlier stage of the tumor type. But ...

Because both Opdivo and Keytruda are approved to treat certain types of cancer, you may be able to switch from one drug to the other. Depending on the cancer being treated, there may be specific ...

Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...

Immunotherapy Increasingly Used in Cancer Care The updates come after the Agency made the decision to limit the use of these agents as monotherapy in patients with metastatic urothelial cancer who ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...